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Objective: To evaluate intraoperative subtenon triamcinolone acetonide (TA) as an adjunct 
to Ahmed glaucoma valve (AGV) implantation.
Design: Retrospective comparative case series.
Participants: Forty-two consecutive cases of uncontrolled glaucoma undergoing AGV implan-
tation: 19 eyes receiving intraoperative subtenon TA and 23 eyes that did not receive TA.
Methods: A retrospective chart review was performed on consecutive pseudophakic adult 
patients with uncontrolled glaucoma undergoing AGV with and without intraoperative subtenon 
TA injection by a single surgeon. Clinical data were collected from 42 eyes and analyzed for 
the first 6 months after surgery.
Main outcome measures: Primary outcomes included intraocular pressure (IOP) and number 
of glaucoma medications prior to and after AGV implantation. The hypertensive phase (HP) 
was defined as an IOP measurement of greater than 21 mmHg (with or without medications) 
during the 6-month postoperative period that was not a result of tube obstruction, retraction, 
or malfunction. Postoperative complications and visual acuity were analyzed as secondary 
outcome measures. 
Results: Five out of 19 (26%) TA cases and 12 out of 23 (52%) non-TA cases developed the 
HP (P=0.027). Mean IOP (14.2±4.6 in TA cases versus [vs] 14.7±5.0 mmHg in non-TA cases; 
P=0.78), and number of glaucoma medications needed (1.8±1.3 in TA cases vs 1.6±1.1 in the 
comparison group; P=0.65) were similar between both groups at 6 months. Although rates of 
serious complications did not differ between the groups (13% in the TA group vs 16% in the 
non-TA group), early tube erosion (n=1) and bacterial endophthalmitis (n=1) were noted with 
TA but not in the non-TA group.
Conclusions: Subtenon TA injection during AGV implantation may decrease the occurrence 
of the HP but does not alter the ultimate IOP outcome and may pose increased risk of serious 
complications within the first 6 months of surgery.
Keywords: Ahmed valve, hypertensive phase, triamcinolone
Introduction
Glaucoma drainage devices have become a valuable tool in the surgical management 
of refractory glaucoma. They are effective in reducing intraocular pressure (IOP) 
and are especially useful in cases where there is high risk of failure for a filtering 
procedure.1,2 The Ahmed glaucoma valve (AGV) is widely used because of the set 
internal resistance that obviates the need for modifications to the implant at the time 
of surgery to prevent postoperative hypotony. 
The AGV has been shown to have comparable intermediate-term efficacy with 
its nonvalved counterpart, the Baerveldt glaucoma implant (BGI), in two prospective 
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randomized clinical trials.3,4 However, the AGV resulted in 
slightly less IOP lowering compared with the BGI. Insertion 
of the AGV has been shown to be associated with a hyperten-
sive phase (HP), a period of time in the early postoperative 
course when the IOP rises.5,6 The development of the HP has 
been shown to be associated with higher final IOP.6 Although 
some studies have shown that this early IOP elevation 
resolves in a subset of patients, in a significant number of 
patients IOP-lowering medications are required to maintain 
IOP control in the longer term.6 Encapsulation of the plate 
early in the postoperative period is thought to be responsible 
for decreased aqueous flow through the AGV, resulting in this 
early rise in IOP.7 Tenon’s cysts that are clinically observed 
in patients after AGV implantation support the notion that 
distal resistance is the primary mechanism for early IOP 
elevation.8 There is also evidence to suggest that proinflam-
matory cytokines are found at higher levels in aqueous of 
eyes with encapsulated blebs and higher IOP.9 Therefore, 
wound modulation and anti-inflammatory agents may help 
minimize this HP. 
Steroids are potent anti-inflammatory agents that may 
help treat the HP and improve IOP control after AGV 
implantation. Intravitreal triamcinolone acetonide (TA) has 
been used in AGV implantation for patients with neovascular 
glaucoma and has been shown to lower mean IOP in the first 
month after surgery. However, TA did not alter intermediate-
term success or complications with AGV implantation in this 
cohort.10 On the other hand, topical steroids were associated 
with a higher rate of the HP compared with topical nonsteroi-
dal agents in another study.11
Subtenon TA is an established route of administering 
steroid locally for cases of macular edema and uveitis.12 It 
may be a more practical route of administration of steroid 
compared with intravitreal injections in patients with refrac-
tory glaucoma. Although complication rates are low with 
intravitreal injections, there is potential risk of prolonged IOP 
elevation, endophthalmitis, retinal detachment, and intraocu-
lar hemorrhage.13 We hypothesize that subtenon TA injection 
is a safe and effective adjunct to AGV implantation that may 
blunt the HP and improve postoperative IOP control.
Methods
The Massachusetts Eye and Ear Human Subjects Committee 
approved this retrospective study. To test our hypothesis that 
TA improves the HP after AGV implantation, we retrospec-
tively reviewed consecutive adult cases of AGV implantation 
by a single surgeon (LRP), and analyzed postoperative data 
for the first 6 months. A series of consecutive pseudophakic 
patients with uncontrolled glaucoma necessitating AGV 
implantation received subtenon TA at the time of surgery 
from 2009 to 2010. All pseudophakic patients receiving an 
AGV during the study period received subtenon TA with 
no specific clinical indications for the TA. A historical 
comparison group consisted of consecutive pseudophakic 
patients who had AGV implantation without subtenon TA 
from 2007 to 2008. Patients who received a pediatric AGV 
(model FP8) or had any concurrent eye surgery were excluded 
from the analysis. 
In both groups, insertion of the AGV (using the FP7 model 
in all cases except in three cases where the S2 model was 
used) was performed in either the superotemporal or 
  inferotemporal quadrant via a fornix-based conjunctival flap. 
Inferior placement of the AGV was performed in cases where 
there was an existing superior glaucoma drainage device or 
if there was conjunctival scarring superiorly that precluded 
placement in that quadrant. The AGV was routinely primed 
with balanced salt solution prior to insertion, and dehydrated 
donor pericardium or irradiated split thickness corneal grafts 
were used for scleral reinforcement. A total of 0.5 mL of sub-
tenon TA (40 mg/mL) was injected adjacent to the site of the 
AGV insertion at the completion of the case. Postoperatively, 
all patients were placed on routine topical broad-spectrum 
antibiotics and topical steroids (prednisolone acetate 1% four 
times daily tapered over a 4-week period).
Primary outcomes include IOP and number of glaucoma 
medications, and secondary outcomes include postoperative 
complications and visual acuity. IOP measurements and 
glaucoma medications were collected from all postopera-
tive visits within 6 months of surgery for each patient. The 
peak IOP for each patient was defined as the highest IOP 
measurement recorded during this time period. For data not 
available at a given time point, that patient was censored in 
the analysis for that time point. We selected our definition of 
the HP based on definitions used in the literature.5,6 The HP 
is defined as an IOP measurement of greater than 21 mmHg 
(with or without medications) during the 6-month post-
operative period that was not a result of tube obstruction, 
retraction, or malfunction. Tube and valve function was 
determined postoperatively by examining the AGV and, if 
needed, needling the bleb with a 30-gauge needle to evalu-
ate aqueous egress and subsequent IOP lowering to suggest 
proper valve function. Given the retrospective nature of this 
study, the initiation of IOP-lowering medications was not 
standardized postoperatively, so we opted to use an IOP-
based definition that does not account for medication use. 
We assessed the number of IOP-lowering medications used Clinical Ophthalmology 2014:8 submit your manuscript | www.dovepress.com
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pre- and postoperatively, as well as timing and number of 
needlings performed in a separate analysis. For secondary 
outcomes, events considered as serious early complications 
include endophthalmitis, hypotony requiring intervention, 
reoperation, tube erosion, and vision loss to light or no light 
perception within the 6-month postoperative period. Any 
patients requiring reoperation for uncontrolled IOP were 
censored from data analysis after reoperation. 
Quantitative data are expressed as mean ± standard devia-
tion, and qualitative data are presented as percentages. To 
compare the TA and non-TA groups, an unpaired t-test was 
used for quantitative data and a chi-square test was used for 
qualitative data. t-tests were two-tailed, and P-values less 
than 0.05 were considered to be statistically significant. 
Results
The two groups were similar in all baseline characteristics, and 
the most common diagnoses in both groups were open angle 
glaucoma and neovascular glaucoma (Table 1). More patients 
in the non-TA group developed the HP compared with the TA 
group (52% versus [vs] 26%, P=0.027) (Table 2). When we 
included only the patients who received a model FP7 Ahmed 
valve (N=39) in a secondary analysis, there was still a statis-
tically significant difference between the two groups (52% 
vs 25%, P=0.020). The mean peak IOP   postoperatively was 
higher in the non-TA group (26±14 mmHg) compared with 
the TA group (19.4±3.9 mmHg), but this trend did not meet 
statistical significance (P=0.059) (Table 2). Although this 
retrospective study was not designed to determine exact timing 
of the HP phase, the patients in the comparison group appeared 
to develop the HP earlier than patients in the TA group (mean 
days to HP were 20 in the non-TA group vs 90 in the TA group, 
P=0.004). Mean IOP and number of glaucoma medications 
used were similar in both groups at every time point, except 
at month 1, when the non-TA group used a higher number of 
medications compared with the TA group (0.9 vs 0.2 medica-
tions, P=0.03) (Table 3). More patients underwent needling 
in the non-TA group (26%) compared with the TA group 
(16%), but this did not meet statistical significance. Those 
who underwent needling in the TA group had it performed 
later compared with the non-TA group (average of 64 days 
vs 18 days, P=0.005). This is consistent with the seemingly 
delayed onset of the HP in the TA group compared with the 
non-TA group. Rates of success (defined as IOP 21 mmHg 
and at least a 20% decrease from preoperative IOP) were 
similar in both groups (87% in the comparison group and 89% 
in the TA group) at 6 months (Table 2). Mean visual acuity 
was similar in both groups at month 6 (Table 2).
The rate of serious complications was similar in both 
groups, but the nature of complications differed between 
Table 1 Baseline demographic and ocular characteristics
Non-TA group 
N=23
TA group 
N=19
P-value
average age, years 66.3±17.4 67.9±11.5 0.73*
sex
Female 11 (48%) 12 (63%) 0.17†
Male 12 (52%) 7 (37%)
race, white 17 (76%) 14 (74%) 0.40†
location of tube
superior 17 (74%) 11 (58%) 0.10†
inferior 6 (26%) 8 (42%)
Diagnosis
Open angle glaucoma 8 6 0.24†
neovascular glaucoma  5 7
Pseudoexfoliation glaucoma 2 3
Chronic angle closure glaucoma 5 1
Uveitic glaucoma 1 2
Traumatic glaucoma 1 0
aphakic glaucoma 1 0
Mean number of prior ocular surgeries 2.0±1.1 1.8±0.9 0.53*
Patients with prior glaucoma surgery 12 (52%) 10 (52%) 0.40†
Mean preoperative intraocular pressure (mmhg) 29.2±9.3 25.7±6.4 0.18*
Mean number of preoperative medications 3.6±1.3 3.6±1.0 0.99*
Mean preoperative visual acuity (logMar) 0.81±0.9 0.56±0.5 0.27*
Notes: *Unpaired t-test; †chi-square test.
Abbreviations: logMar, log of the minimum angle of resolution; Ta, triamcinolone acetonide.Clinical Ophthalmology 2014:8 submit your manuscript | www.dovepress.com
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the groups. In the non-TA group, serious complications 
included reoperation for uncontrolled IOP in two patients 
and vision loss from light perception to no light perception 
in one patient. No tube erosions or cases of endophthalmitis 
were noted in the non-TA group in the 6-month postopera-
tive period. 
In the TA group, penetrating keratoplasty for corneal 
  decompensation was performed in one patient postop-
eratively at month 5. None of the patients in the TA group 
required reoperation for uncontrolled IOP in the 6-month 
postoperative period. The second serious complication noted 
in the TA group was tube erosion at month 2 in a patient 
with an inferotemporal tube who had no intraoperative 
complications with conjunctival dissection and closure. This 
patient was treated with tube explantation and transscleral 
cyclophotocoagulation. The third serious complication 
in the TA group was a case of bacterial endophthalmitis 
associated with an inferotemporal tube. The patient had 
two prior trabeculectomies with solid superior blebs that 
were not cystic in morphology. The patient presented with 
significant intraocular inflammation, but no tube erosion, 
6 weeks after surgery and was treated with vitreous biopsy, 
intravitreal injection of antibiotics, and tube explantation. The 
infection was confirmed with vitreous cultures that grew out 
methicillin-sensitive Staphylococcus aureus. The infection 
resolved, but the patient was noted to have significant scleral 
thinning in the inferotemporal quadrant where the Ahmed 
valve was initially implanted. 
Discussion
Our study suggests that intraoperative subtenon TA injection 
with AGV implantation decreases occurrence of the HP. The 
TA group had lower mean peak IOP overall, though this 
did not reach statistical significance, probably due to the 
wide variability in peak IOP in both groups. The lower rate 
of the HP in the TA group is potentially a result of wound-
modulating and anti-inflammatory properties of steroids. 
Indirect evidence supporting this comes from observations 
made in the patients who received TA. The patient with the 
tube erosion in the TA group developed the erosion over the 
Table 2 early outcomes after ahmed valve implantation
Non-TA group 
N=23
TA group 
N=19
P-value
Mean peak iOP (mmhg) 26±14.2 19.4±3.9 0.059*
range of peak iOP (mmhg) 10 to 40 12 to 28
Patients with iOP 21 mmhg 12 (52%) 5 (26%) 0.027†
Patients who underwent needling 6 (26%) 3 (16%) 0.21†
Mean time to needling (days) 18±11 64±24 0.005*
Mean iOP at 6 months (mmhg) 14.2±4.6 14.7±5.0 0.78*
Mean number of medications at 6 months 1.8±1.3 1.6±1.1 0.65*
Mean visual acuity (logMar) at 6 months 0.77±0.9 0.64±0.6 0.56*
Patients with success (iOP 21 mmhg and 20% decrease in iOP) 20 (87%) 17 (89%) 0.31†
Patients with serious complications 3 (13%) 3 (16%) 0.32†
Notes: *Unpaired t-test; †chi-square test.
Abbreviations: iOP, intraocular pressure; logMar, log of the minimum angle of resolution; Ta, triamcinolone acetonide.
Table 3 iOP and glaucoma medications used at follow-up
Mean IOP (mmHg) Number of medications
Non-TA group TA group P-value* Non-TA group TA group P-value*
Preoperative 29.2±9.3 25.7±6.4 0.181 3.6±1.3 3.6±1.0 0.989
Day 1 8.5±6.2 7.7±5.0 0.330 0.1±0.3 0.1±0.3 0.845
week 2 16.2±16.0 11.3±5.7 0.210 0.3±0.7 0.1±0.3 0.344
Month 1 18.0±10.8 14.1±5.7 0.192 0.9±1.1 0.2±0.5 0.028
week 6 15.9±6.9 16.1±4.2 0.950 1.4±1.1 0.8±1.1 0.227
Month 2 14.3±4.4 14.1±5.0 0.929 1.5±1.2 1.4±1.6 0.761
Month 3 15.8±6.0 16.1±6.7 0.924 1.8±1.3 1.4±1.4 0.414
Month 4 14.3±8.2 15.6±5.4 0.711 1.8±1.2 1.3±1.5 0.328
Month 6 14.2±4.6 14.7±5.0 0.800 1.8±1.3 1.6±1.1 0.654
Note: *Unpaired t-test.
Abbreviations: iOP, intraocular pressure; Ta, triamcinolone acetonide.Clinical Ophthalmology 2014:8 submit your manuscript | www.dovepress.com
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inferior tube early in the postoperative course (2 months). 
Tube erosions have been noted to occur in up to 8.3% of 
patients with inferior AGV,14 but the mean time to initial 
tube erosion has been reported to be 21.5 months.15 The 
patient with bacterial endophthalmitis in the TA group did 
not have tube erosion but was noted to have notable scleral 
thinning at and around the site of the explanted tube shunt. 
Endophthalmitis is fairly uncommon after glaucoma drain-
age device implantation (1.7% in superotemporal AGV16 and 
2.5% in inferior AGV14). Although the scleral thinning 
is likely a direct sequela of the infection in this case, any 
additional adverse effect of the TA in this setting is unclear. 
These unusual early complications suggest that TA may be 
exerting a potent local effect on the tissues.
Although the TA group did have more inferiorly placed 
tubes compared with the control group (42% in TA vs 
26% in controls, P=0.10), this did not reach statistical 
significance. However, it is worth noting that the patients 
with the early tube erosion and endophthalmitis in the TA 
group both had the AGV implanted in the inferotemporal 
quadrant. Though none of the non-TA cases with inferior 
tubes developed early serious complications, inferior place-
ment of glaucoma drainage devices has been shown to be 
associated with more complications, in general.14,17,18 Based 
on our findings, we caution against use of adjunctive sub-
tenon steroids in an inferiorly placed AGV, because of the 
potentially additive risks. 
Although the rate of the HP was lower in the TA group, 
the mean IOP and number of glaucoma medications used 
at 6 months were similar in both groups. The 6-month 
IOP outcomes and success rates we report for both groups 
are comparable with previously published results on the 
AGV.2–4 Compared with cohorts in prospective studies com-
paring AGV with BGI, our cohort had slightly lower mean 
IOP (14.2 mmHg in the non-TA group and 14.7 mmHg in 
the TA group compared with 15.7 mmHg and 16.7 mmHg 
in the Ahmed Baerveldt Comparison Study3 and Ahmed 
Versus Baerveldt Study4 trials, respectively) on a similar 
average number of medications at 6 months. Prior studies 
using antimetabolites and antivascular endothelial growth 
factor agents as adjuncts to Ahmed valve implantation simi-
larly found no difference in final outcomes with adjunctive 
treatment.19–22 
Although a prospective evaluation of postoperative IOP 
would be needed to better characterize the timing of the HP, 
it is interesting that the HP appeared to occur sooner in the 
non-TA group compared with the TA group. The delayed 
HP in patients in the TA group may reflect the diminishing 
effect of the subtenon TA over time. The unchanged IOP and 
  medication outcomes at 6 months between the two groups 
may reflect the loss of effect of TA over time or inadequate 
dosing of the medication. Improved drug delivery systems that 
would potentiate longer-term release of wound-  modulating 
agents may be needed to see a difference in longer-term 
outcomes. One of the weaknesses of our study is the short 
follow-up period, which does not allow us to address out-
comes beyond 6 months. The primary aim of this study is to 
describe the safety and early effects of TA on the HP, which, 
by definition, occurs within the first 6 months of surgery.   
As our findings do not support the use of subtenon TA at 
Ahmed valve implantation, longer follow-up is not needed.
Although this is the first published report of the early out-
comes of subtenon TA during AGV implantation, this study 
has other limitations. The retrospective, nonrandomized 
design of this study makes it prone to bias and unintended 
differences between the two groups. Although not statisti-
cally significant, the higher proportion of inferior AGVs 
in the TA group suggests that the TA group may have had 
subjects with more complex ophthalmic disease requiring 
inferior tube implantation. However, both groups had similar 
mean preoperative IOP, visual acuity, number of prior ocular 
surgeries, and preoperative glaucoma medications at baseline 
(Table 1). The postoperative medication regimen was also 
not standardized for all the patients. IOP-lowering medica-
tions were started at the discretion of the surgeon and not at 
a preset IOP level. Although the mean number of medica-
tions was similar between groups for most time points, the 
threshold to start these medications may have differed and 
may be another uncontrolled factor. Evidence showing that 
intraocular cytokine levels are related to IOP provides a basis 
for judicious IOP control after glaucoma drainage device 
implantation.9 If better IOP control in the early postoperative 
period decreases the risk of the HP, then a lower threshold 
in starting IOP-lowering medications postoperatively may 
influence final outcomes. 
Another limitation to this study is the method of deliver-
ing TA. There was reflux of medication noted in some cases, 
so a precise dosing of TA was likely not achieved. The 
ideal dose and mode of delivery have yet to be determined. 
Microfilms are being developed to carry various types of 
ocular medications and may be a more standardized method 
to deliver steroids at the time of surgery.23,24 More study is 
needed to evaluate the ideal delivery of adjunctive steroids 
during AGV implantation to prevent encapsulation with its 
attendant poor hydraulic conductivity of aqueous humor. The 
use of fibrin glue at the time of AGV implantation may also Clinical Ophthalmology
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help minimize intra- and postoperative inflammation, and 
may be another avenue to explore in preventing the HP.25 
Conclusion
In conclusion, we do not advocate the use of intraoperative 
subtenon TA as an adjunctive measure to prevent the HP 
phase, especially for inferior AGV implantation. Given the 
comparable mean IOP between TA and non-TA cases at 
6 months, and the development of endophthalmitis in a TA 
case, other measures to address the HP should be employed. 
Short-term measures such as bleb needling and the intro-
duction of glaucoma medicines seem to represent a safer 
approach to address the HP. 
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